Identification of a tumour associated antigen in lung cancer patients with asbestos exposure

Anticancer Res. 2010 Jul;30(7):2631-9.


Background: This study analysed the humoral immune response in asbestos exposed lung cancer patients to identify new surrogate markers of the carcinogenic risk in populations exposed to asbestos.

Methods and results: A serological analysis identified five distinct antigens reactive with IgG derived from a lung cancer patient with high asbestos exposure. In one of the isolated antigens, quantitative RT-PCR indicated that annexin A2 (AnxA2) was overexpressed in lung cancer tissues and normal lung from patients with high asbestos exposure. Antibody against AnxA2 was detected in 9/15 (60%) of lung cancer patients with high asbestos exposure; however, in only 1/12 (8%) of lung cancer patients with low asbestos exposure. AnxA2 was also overexpressed in malignant mesothelioma cells, and the antibody was also positive in 8/15 (53%) of patients with malignant mesothelioma.

Conclusion: The antibody titer against AnxA2 may be a potentially useful new diagnostic surrogate marker for asbestos-related lung cancer and malignant mesothelioma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Annexin A2 / biosynthesis
  • Annexin A2 / immunology
  • Antibodies, Neoplasm / immunology
  • Antigens, Neoplasm / immunology*
  • Asbestos / immunology
  • Asbestos / poisoning*
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immunity, Humoral / immunology
  • Immunoglobulin G / immunology
  • Interleukin-6 / blood
  • Interleukin-6 / immunology
  • Lung Neoplasms / etiology*
  • Lung Neoplasms / immunology*
  • Male
  • Mesothelioma / etiology
  • Mesothelioma / immunology
  • Reverse Transcriptase Polymerase Chain Reaction


  • ANXA2 protein, human
  • Annexin A2
  • Antibodies, Neoplasm
  • Antigens, Neoplasm
  • Immunoglobulin G
  • Interleukin-6
  • Asbestos